DrugPatentWatch Database Preview

Lenvatinib mesylate - Generic Drug Details

« Back to Dashboard

What are the generic sources for lenvatinib mesylate and what is the scope of lenvatinib mesylate patent protection?

Lenvatinib mesylate is the generic ingredient in one branded drug marketed by Eisai Inc and is included in one NDA. There are three patents protecting this compound. Additional information is available in the individual branded drug profile pages.

There is one drug master file entry for lenvatinib mesylate. One supplier is listed for this compound.

Summary for lenvatinib mesylate

US Patents:	3
Tradenames:	1
Applicants:	1
NDAs:	1
Drug Master File Entries:	1
Suppliers / Packagers:	1
Bulk Api Vendors:	20
Clinical Trials:	2
Patent Applications:	15
DailyMed Link:	lenvatinib mesylate at DailyMed

Pharmacology for lenvatinib mesylate

Drug Class	Kinase Inhibitor
Mechanism of Action	Receptor Tyrosine Kinase Inhibitors

Synonyms for lenvatinib mesylate

3J78384F61

4-[3-Chloro-4-[[(cyclopropylamino)carbonyl]amino]phenoxy]-7-methoxy-6-quinolinecarboxamide monomethanesulfonate

6-carbamoyl-4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinolin-1-ium methanesulfonate

6-Quinolinecarboxamide, 4-(3-chloro-4-(((cyclopropylamino)carbonyl)amino)phenoxy)- 7-methoxy-, methanesulfonate (1:1)

857890-39-2

AKOS030632716

CHEBI:85995

CHEMBL2105704

D09920

DTXSID90235081

HE071028

KB-145996

KS-00000TO1

Lenvatinib mesilate

Lenvatinib mesilate (JAN)

Lenvatinib mesylate (USAN)

Lenvatinib mesylate [USAN]

LENVATINIB; METHANESULFONIC ACID

Lenvima (TN)

methanesulfonic acid--4-{3-chloro-4-[(cyclopropylcarbamoyl)amino]phenoxy}-7-methoxyquinoline-6-carboxamide (1/1)

MFCD18633219

N-(4-((6-Carbamoyl-7-methoxyquinolin-4-yl)oxy)-2-chlorophenyl)-N'-cyclopropylurea monomethanesulfonate

SCHEMBL865174

UNII-3J78384F61

US Patents and Regulatory Information for lenvatinib mesylate

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-002	Feb 13, 2015		RX	Yes	Yes			Y	Y
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-002	Feb 13, 2015		RX	Yes	Yes
Eisai Inc	LENVIMA	lenvatinib mesylate	CAPSULE;ORAL	206947-001	Feb 13, 2015		RX	Yes	No			Y	Y

International Patents for lenvatinib mesylate

Country	Document Number	Estimated Expiration
Hungary	S1600009
Israel	175933
Canada	2426461
Norway	326781

Supplementary Protection Certificates for lenvatinib mesylate

Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
15/050	Ireland		PRODUCT NAME: LENVATINIB OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF OR A HYDRATE THEREOF; REGISTRATION NO/DATE: EU/1/15/1002/001-/002 20150528
2015000083	Germany		PRODUCT NAME: LENVATINIB ODER EINES SEINER PHARMAZEUTISCH AKZEPTABLEN SALZE ODER EINES SEINER HYDRATE; REGISTRATION NO/DATE: EU/1/15/1002/001-002 20150528
2015039	Lithuania		PRODUCT NAME: LENVATINIBUM; REGISTRATION NO/DATE: EU/1/15/1002/001 - 002 20150528
858	Luxembourg		PRODUCT NAME: LENVATINIB, OU UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES OU UN HYDRATE DE CELUI-CI